Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist
- 11 May 2007
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 322 (2), 477-485
- https://doi.org/10.1124/jpet.106.118927
Abstract
In neutrophils, growth-related protein-α (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants (Cytokine14:27–36, 2001; Biochemistry42:2874–2886, 2003) and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2. The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small molecule antagonists for these receptors. The data presented herein describe the pharmacology of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2. Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist. Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine. The pharmacological specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors. To measure compound affinity, we characterized [3H]Sch527123 in both equilibrium and nonequilibrium binding analyses. Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible. Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9 ± 0.3 nM), the compound is CXCR2-selective (Kd = 0.049 ± 0.004 nM). Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.Keywords
This publication has 30 references indexed in Scilit:
- A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary InflammationThe Journal of pharmacology and experimental therapeutics, 2007
- Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 AntagonistAntimicrobial Agents and Chemotherapy, 2005
- COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstructionAmerican Journal of Physiology-Renal Physiology, 2005
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndromeCritical Care Medicine, 2002
- Interleukin-8 receptor antagonists in pulmonary diseasesCurrent Opinion in Pharmacology, 2001
- Discrete Steps in Binding and Signaling of Interleukin-8 with Its ReceptorJournal of Biological Chemistry, 1996
- CXC Chemokines Bind to Unique Sets of Selectivity Determinants That Can Function Independently and Are Broadly Distributed on Multiple Domains of Human Interleukin-8 Receptor BPublished by Elsevier BV ,1996
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973